-
-
-
-
-
-
-
GSK cut to Hold by Berenberg as investors await proof from upcoming drug launches
-
-
-
-
-
-
-
Guggenheim Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
-
-
-
-
-
-
-
GSK raises $1.5 billion from sale of remaining Haleon stake
-
-
-
-
-
-
-
GSK sees strong growth as Haleon split and vaccine drive pays off
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
-
-
-
-
-
-
-
GlaxoSmithKline (GSK) Posts Q3 Results, Lifts Outlook
-
-
-
-
-
-
-
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2
-
1,198,729 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

